Intralymphatic injection of autoantigen in type 1 diabetes

New England Journal of Medicine

Volumn 376, Issue 7, 2017, Pages 697-699

  Ludvigsson, Johnny ^a   Wahlberg, Jeanette ^a   Casas, Rosaura ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HEMOGLOBIN A1C; INTERLEUKIN 10; INTERLEUKIN 2; TUMOR NECROSIS FACTOR; VITAMIN D; AUTOANTIGEN; GLUTAMATE DECARBOXYLASE; VITAMIN;

CELL FUNCTION; CELL PROLIFERATION; DISEASE DURATION; HUMAN; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; PANCREAS ISLET BETA CELL; TH1 CELL; TH2 CELL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; ADVERSE EFFECTS; AREA UNDER THE CURVE; BLOOD; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; EPIDEMIOLOGY; INTRALYMPHATIC DRUG ADMINISTRATION; PILOT STUDY; YOUNG ADULT;

AREA UNDER CURVE; AUTOANTIGENS; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; GLUTAMATE DECARBOXYLASE; HISTORICALLY CONTROLLED STUDY; HUMANS; INJECTIONS, INTRALYMPHATIC; PILOT PROJECTS; VITAMIN D; VITAMINS; YOUNG ADULT;

EID: 85013482359     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1616343     Document Type: Letter

References (5)

1. Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, Ludvigsson J. GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-Analysis. Diabetologia 2017; 60: 43-9.
2. Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366: 433-42.
3. Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial. Lancet 2011; 378: 319-27.
4. Bizzarri C, Pitocco D, Napoli N, et al. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: The IMDIAB XIII trial. Diabetes Care 2010; 33: 1962-3.
5. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54: 1763-9.